Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

p53 ubiquitination: Mdm2 and beyond.

Christopher L Brooks1, Wei Gu

  • 1Institute for Cancer Genetics and Department of Pathology, College of Physicians and Surgeons, Columbia University, 1150 St. Nicholas Avenue, New York, New York 10032, USA.

Molecular Cell
|February 4, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2022
Same author

A Response to: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab".

Advances in therapy·2022
Same author

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.

Advances in therapy·2022
Same author

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.

The Journal of clinical investigation·2019
Same author

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

The New England journal of medicine·2019
Same author

Ferroptosis: A missing puzzle piece in the p53 blueprint?

Molecular & cellular oncology·2016
Same journal

Thyroid cancer-associated EZH1 Q571R mutation drives chromatin compaction and H3K27me3 invasion into active chromatin.

Molecular cell·2026
Same journal

Genome-wide rotational and translational phasing of nucleosomes with human transcription factors.

Molecular cell·2026
Same journal

Spliceosomal proofreading factors safeguard 3' splice-site fidelity and prevent proteotoxicity and inflammation.

Molecular cell·2026
Same journal

Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTP.

Molecular cell·2026
Same journal

A bacterial reverse transcriptase: Protein-templated DNA synthesis fuels antiviral immunity.

Molecular cell·2026
Same journal

Tweezing apart ribosome heterogeneity.

Molecular cell·2026
See all related articles

The Mdm2 oncoprotein is not the sole factor in p53 tumor suppressor degradation. Research reveals a complex pathway involving multiple proteins that regulate p53 ubiquitination and turnover.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cellular Regulation

Background:

  • Early research identified Mdm2 as the primary E3 ubiquitin ligase for the p53 tumor suppressor.
  • The p53 pathway is crucial for preventing tumor formation.
  • Understanding p53 regulation is vital for cancer therapy.

Purpose of the Study:

  • To explore the complexity of p53 ubiquitination and degradation.
  • To investigate the roles of other proteins in regulating p53.
  • To challenge the conventional view of Mdm2's essential role in p53 turnover.

Main Methods:

  • Literature review of recent studies on p53 regulation.
  • Analysis of the known interactions between p53, Mdm2, and other regulatory proteins.
  • Comparative analysis of different ubiquitination and degradation pathways.

Related Experiment Videos

Main Results:

  • Multiple proteins, including MdmX, HAUSP, ARF, COP1, Pirh2, and ARF-BP1, are involved in p53 regulation.
  • These proteins contribute to the multifaceted nature of p53 ubiquitination and degradation.
  • Mdm2 plays a significant role but is not exclusively essential for p53 turnover.

Conclusions:

  • The regulation of p53 ubiquitination and degradation is more complex than previously understood.
  • The discovery of novel regulatory proteins highlights the intricate network controlling p53.
  • Future research should consider the interplay of multiple factors in p53 regulation and its implications for cancer.